Segment, Geographic and Other Revenue Information (Tables)

6 Months Ended

Jul. 03, 2022

Schedule of Segment Reporting Information by Segment


The following provides selected income statement information by reportable segment:
	Three Months Ended								Six Months Ended
	Revenues				Earnings(a)				Revenues				Earnings(a)
(MILLIONS)	July 3, 2022		July 4, 2021		July 3, 2022		July 4, 2021		July 3, 2022		July 4, 2021		July 3, 2022		July 4, 2021
Reportable Segment:
Biopharma	$	27,425	$	18,463	$	17,223	$	9,816	$	52,748	$	32,588	$	30,662	$	18,199
Other business activities(b)	317		437		(3,441)		(2,524)		655		827		(5,917)		(4,571)
Reconciling Items:
Amortization of intangible assets	—		—		(822)		(928)		—		—		(1,657)		(1,798)
Acquisition-related items	—		—		(82)		(34)		—		—		(269)		27
Certain significant items(c)	—		—		(1,431)		618		—		—		(2,322)		784
	$	27,742	$	18,899	$	11,447	$	6,949	$	53,402	$	33,415	$	20,497	$	12,641

(a)Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $69 million in the second quarter of 2022 and $62 million in the second quarter of 2021, and $125 million in the first six months of 2022 and $89 million in the first six months of 2021.

(b)Other business activities include revenues and costs associated with PC1, as well as costs that we do not allocate to our operating segments, per above. Included in earnings in the second quarter and first six months of 2022 is a $450 million write-off to Cost of sales of inventory related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used.

(c)Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). For earnings in the second quarter and first six months of 2022, includes, among other items, net losses on equity securities of $539 million and $1.2 billion, respectively, recorded in Other (income)/deductions––net. For earnings in the second quarter and first six months of 2021, includes, among other items, net gains on equity securities of $798 million and $1.2 billion, respectively, recorded in Other (income)/deductions––net.

Schedule of Revenues by Geographic Region


The following summarizes revenues by geographic area:
	Three Months Ended					Six Months Ended
(MILLIONS)	July 3, 2022		July 4, 2021		% Change	July 3, 2022		July 4, 2021		% Change
United States	$	11,222	$	7,515	49	$	20,140	$	15,046	34
Developed Europe	5,480		4,577		20	11,569		7,615		52
Developed Rest of World	5,034		2,997		68	8,320		4,120		102
Emerging Markets	6,006		3,810		58	13,373		6,634		102
Revenues	$	27,742	$	18,899	47	$	53,402	$	33,415	60

Schedule of Significant Product Revenues

The following provides detailed revenue information for several of our major products:


(MILLIONS)		Three Months Ended				Six Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	July 3, 2022		July 4, 2021		July 3, 2022		July 4, 2021
TOTAL REVENUES(a)		$	27,742	$	18,899	$	53,402	$	33,415
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)(a), (b)		$	27,425	$	18,463	$	52,748	$	32,588
Vaccines		$	10,459	$	9,234	$	25,399	$	14,127
Comirnaty direct sales and alliance revenues	Active immunization to prevent COVID-19	8,848		7,838		22,075		11,300
Prevnar family(c)	Pneumococcal disease	1,429		1,241		2,994		2,524
Nimenrix	Meningococcal ACWY disease	65		49		142		95
FSME-IMMUN/TicoVac	Tick-borne encephalitis disease	68		61		110		114
All other Vaccines	Various	49		46		78		94
Hospital(a)		$	9,714	$	1,745	$	12,905	$	3,630
Paxlovid	COVID-19 infection (high risk population)	8,115		—		9,585		—
Sulperazon	Bacterial infections	210		141		420		334
Ig Portfolio(d)	Various	125		107		232		212
Zavicefta	Bacterial infections	100		104		204		198
Zithromax	Bacterial infections	54		43		180		132
Medrol	Anti-inflammatory glucocorticoid	79		112		155		211
Fragmin	Treatment/prevention of venous thromboembolism	72		77		142		149
Vfend	Fungal infections	54		72		119		153
All other Anti-infectives	Various	367		474		749		929
All other Hospital	Various	537		613		1,120		1,314
Oncology		$	3,088	$	3,145	$	6,055	$	6,007
Ibrance	HR-positive/HER2-negative metastatic breast cancer	1,320		1,404		2,557		2,657
Xtandi alliance revenues	mCRPC, nmCRPC, mCSPC	290		303		558		570
Inlyta	Advanced RCC	274		257		508		486
Zirabev(e)	Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer	138		129		286		215
Bosulif	Philadelphia chromosome–positive chronic myelogenous leukemia	156		136		284		259
Xalkori	ALK-positive and ROS1-positive advanced NSCLC	118		120		244		255
Ruxience(e)	Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis	113		120		237		218
Retacrit(e)	Anemia	106		103		221		212
Sutent	Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor	97		194		211		394
Lorbrena	ALK-positive metastatic NSCLC	77		66		149		126
Bavencio alliance revenues	Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC	58		37		125		68
Aromasin	Post-menopausal early and advanced breast cancer	59		51		121		103
Besponsa	Relapsed or refractory B-cell acute lymphoblastic leukemia	58		45		109		95
Braftovi	In combination with Mektovi for metastatic melanoma in patients with a BRAFV600E/K mutation and, in combination with Erbitux® (cetuximab)(f), for the treatment of BRAFV600E -mutant mCRC after prior therapy	51		42		98		89
Trazimera(e)	HER-positive breast cancer and metastatic stomach cancers	46		41		98		87
Mektovi	In combination with Braftovi for metastatic melanoma in patients with a BRAFV600E/K mutation	44		36		84		71
All other Oncology	Various	82		60		163		102
Internal Medicine		$	2,405	$	2,403	$	4,846	$	4,997
Eliquis alliance revenues and direct sales	Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism	1,745		1,481		3,537		3,124


(MILLIONS)		Three Months Ended				Six Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	July 3, 2022		July 4, 2021		July 3, 2022		July 4, 2021
Premarin family	Symptoms of menopause	115		128		217		271
BMP2	Development of bone and cartilage	75		66		142		115
Toviaz	Overactive bladder	45		62		99		119
Chantix/Champix	An aid to smoking cessation treatment in adults 18 years of age or older	1		184		4		401
All other Internal Medicine	Various	424		482		846		966
Rare Disease		$	909	$	895	$	1,872	$	1,720
Vyndaqel/Vyndamax	ATTR-cardiomyopathy and polyneuropathy	552		501		1,164		953
BeneFIX	Hemophilia B	113		112		225		225
Genotropin	Replacement of human growth hormone	91		109		171		189
Somavert	Acromegaly	64		68		132		133
Refacto AF/Xyntha	Hemophilia A	64		77		129		165
All other Rare Disease	Various	25		29		50		55
Inflammation & Immunology (I&I)		$	850	$	1,041	$	1,671	$	2,107
Xeljanz	RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis	430		586		802		1,124
Enbrel (Outside the U.S. and Canada)	RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis	257		286		537		605
Inflectra(e)	Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis	137		136		272		313
All other I&I	Various	25		33		60		65
PFIZER CENTREONE(b)		$	317	$	437	$	655	$	827
Total Alliance revenues		$	2,317	$	1,880	$	4,631	$	3,650
Total Biosimilars(e)		$	580	$	559	$	1,185	$	1,089
Total Sterile Injectable Pharmaceuticals(g)		$	1,286	$	1,381	$	2,617	$	2,863

(a)On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See Note 1A.

(b)At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($55 million and $101 million for the second quarter and the first six months of 2022, respectively, and $87 million for both the second quarter and the first six months of 2021), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior-period information to conform to the current management structure.

(c)Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult).

(d)Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig.

(e)Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Zirabev, Inflectra, Ruxience, Retacrit and Trazimera.

(f)Erbitux® is a registered trademark of ImClone LLC.

(g)Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.